Jazz Pharmaceuticals plc

NASDAQ:JAZZ

109.45

-0.47 (-0.43%)

4:46:17 PM EDT: $114.50 +5.05 (+4.61%)

Market Cap (Intraday)	6.59B
Current PE	13.68
Forward PE	22.16
2yr Forward PE	5.08

See more stats

Estimates Current Quarter

Revenue	$1.05 Billion
Adjusted EPS	-$7.42

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Jazz Pharmaceuticals plc Stock, NASDAQ:JAZZ

Waterloo Exchange, Waterloo Road, Dublin, Dublin 4

Ireland

Phone: +353.1.634.7800

Number of Employees: 2800

http://www.jazzpharmaceuticals.com

Description

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.